This report describes and explains the ABSL-3 lab services market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global ABSL-3 lab services market reached a value of nearly $530 million in 2025, having grown at a compound annual growth rate (CAGR) of 8.3% since 2020. The market is expected to grow from $530 million in 2025 to $766.2 million in 2030 at a rate of 7.7%. The market is then expected to grow at a CAGR of 7% from 2030 and reach $1.07 billion in 2035.
Growth in the historic period resulted from rising adoption of personalized medicine, expansion of real-world evidence (RWE) and real-world data (RWD) in clinical decisions, rising investments in advanced therapeutic modalities and rising focus on patient-centric care models. Factors that negatively affected growth in the historic period were high capital investment requirements and high rate of clinical trial failures.
Going forward, rising incidence of airborne and high-risk infectious diseases, increasing awareness about zoonotic diseases, growing demand for preclinical infectious disease drug discovery and increased funding for neglected tropical disease (NTD) research will drive the growth. Factors that could hinder the growth of the ABSL-3 lab services market in the future include high ongoing operational and maintenance costs, limited availability of skilled personnel impact of trade war and tariff.
Market trends for the ABSL-3 lab services market include focus on expanding specialized high-containment animal research capabilities, next-generation decentralized biosafety networks for national disease preparedness, government-backed expansion of high-containment animal research facilities and development of regulatory frameworks for high-containment laboratories.
The ABSL-3 lab services market is segmented by disease area into respiratory infections, viral infections and other disease areas. The respiratory infections market was the largest segment of the ABSL-3 lab services market segmented by disease area, accounting for 45.8% or $242.9 million of the total in 2025. Going forward, the viral infections segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by disease area, at a CAGR of 9.4% during 2025-2030.
The ABSL-3 lab services market is segmented by pathogen types into viruses, bacteria, fungi and other pathogen types. The bacteria was the largest segment of the ABSL-3 lab services market segmented by pathogen types, accounting for 54% or $286 million of the total in 2025. Going forward, the viruses segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by pathogen types, at a CAGR of 9.5% during 2025-2030.
The ABSL-3 lab services market is segmented by applications into antiviral research and development (R&D), vaccine efficacy, transmission, other applications. The antiviral research and development (R&D), market was the largest segment of the ABSL-3 lab services market segmented by applications, accounting for 35.6% or $188.8 million of the total in 2025. Going forward, the vaccine efficacy segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by applications, at a CAGR of 8.6% during 2025-2030.
The ABSL-3 lab services market is segmented by species into rodent, non-human primate (NHP) and other species. The rodent market was the largest segment of the ABSL-3 lab services market segmented by species, accounting for 52.6% or $279 million of the total in 2025. Going forward, the other species segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by species, at a CAGR of 8.7% during 2025-2030.
The ABSL-3 lab services market is segmented by service types into efficacy studies, pharmacokinetics/pharmacodynamics (PK/PD) studies, investigational new drug (IND)-enabling packages, supporting assays and other service types. The efficacy studies market was the largest segment of the ABSL-3 lab services market segmented by service types, accounting for 33.8% or $179 million of the total in 2025. Going forward, the investigational new drug (IND)-enabling packages segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by service types, at a CAGR of 8.8% during 2025-2030.
The ABSL-3 lab services market is segmented by end user into pharmaceutical and biotech companies, contract research organizations (CROs), academic and research institutions, not-for-profit research organizations, governmental institutes and public health agencies, defense/military and other end users. The pharmaceutical and biotech companies market was the largest segment of the ABSL-3 lab services market segmented by end user, accounting for 43.9% or $232.9 million of the total in 2025. Going forward, the academic and research institutions segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by end user, at a CAGR of 8.4% during 2025-2030.
The global ABSL-3 (animal biosafety level 3) lab services market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 20.87% of the total market in 2024. University of Pennsylvania (Jurado Lab) was the largest competitor with a 2.81% share of the market, followed by Boston University with 2.70%, University of South Florida (USF Health) with 2.45%, University of South Carolina, with 2.37%, University of Minnesota, with 2.34%, University of California (UC) with 2.13%, Southern Research with 1.81%, Tulane University with 1.62%, Texas Biomed (Texas Biomedical Research Institute) with 1.38% and SoBran, Inc. with 1.25%.
The top opportunities in the ABSL-3 lab services market segmented by disease area will arise in the respiratory infections segment, which will gain $104.8 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by pathogen types will arise in the bacteria segment, which will gain $127.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by applications will arise in the vaccine efficacy segment, which will gain $94.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the rodent segment, which will gain $132.5 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the efficacy studies segment, which will gain $87.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the pharmaceutical & biotech companies segment, which will gain $107.8 million of global annual sales by 2030. The ABSL-3 lab services market size will gain the most in the USA at $78.3 million.
Player-adopted strategies in the ABSL-3 lab services market include focus on expanding their business capabilities through new expansions.
Market-trend-based strategies for the ABSL-3 lab services market include focus on expanding specialized high-containment animal research capabilities, scaling infrastructure through multi-site expansion and partnerships with public institutions to improve geographic coverage and access to certified containment facilities, expanding specialized high-containment animal research capabilities, particularly for non-human primate studies that support advanced vaccine and therapeutic development, and aligning facility design, operations, and quality systems.
To take advantage of the opportunities, the analyst recommends the ABSL-3 (animal biosafety level 3) lab services companies to focus on expanding high-containment animal research capabilities, focus on multi-site infrastructure expansion and public sector partnerships, focus on expanding high-containment animal research capabilities, focus on regulatory alignment and certification readiness, focus on viral infections segment expansion, focus on expanding viral research services, expand in emerging markets, continue to focus on developed markets, focus on expanding and optimizing distribution networks, focus on structured value-based pricing with risk and compliance alignment, build authority through targeted educational promotion, strengthen credibility with proof and precision targeting and focus on skilled talent development and research-aligned engagement.
This product will be delivered within 3-5 business days.
The global ABSL-3 lab services market reached a value of nearly $530 million in 2025, having grown at a compound annual growth rate (CAGR) of 8.3% since 2020. The market is expected to grow from $530 million in 2025 to $766.2 million in 2030 at a rate of 7.7%. The market is then expected to grow at a CAGR of 7% from 2030 and reach $1.07 billion in 2035.
Growth in the historic period resulted from rising adoption of personalized medicine, expansion of real-world evidence (RWE) and real-world data (RWD) in clinical decisions, rising investments in advanced therapeutic modalities and rising focus on patient-centric care models. Factors that negatively affected growth in the historic period were high capital investment requirements and high rate of clinical trial failures.
Going forward, rising incidence of airborne and high-risk infectious diseases, increasing awareness about zoonotic diseases, growing demand for preclinical infectious disease drug discovery and increased funding for neglected tropical disease (NTD) research will drive the growth. Factors that could hinder the growth of the ABSL-3 lab services market in the future include high ongoing operational and maintenance costs, limited availability of skilled personnel impact of trade war and tariff.
Market trends for the ABSL-3 lab services market include focus on expanding specialized high-containment animal research capabilities, next-generation decentralized biosafety networks for national disease preparedness, government-backed expansion of high-containment animal research facilities and development of regulatory frameworks for high-containment laboratories.
The ABSL-3 lab services market is segmented by disease area into respiratory infections, viral infections and other disease areas. The respiratory infections market was the largest segment of the ABSL-3 lab services market segmented by disease area, accounting for 45.8% or $242.9 million of the total in 2025. Going forward, the viral infections segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by disease area, at a CAGR of 9.4% during 2025-2030.
The ABSL-3 lab services market is segmented by pathogen types into viruses, bacteria, fungi and other pathogen types. The bacteria was the largest segment of the ABSL-3 lab services market segmented by pathogen types, accounting for 54% or $286 million of the total in 2025. Going forward, the viruses segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by pathogen types, at a CAGR of 9.5% during 2025-2030.
The ABSL-3 lab services market is segmented by applications into antiviral research and development (R&D), vaccine efficacy, transmission, other applications. The antiviral research and development (R&D), market was the largest segment of the ABSL-3 lab services market segmented by applications, accounting for 35.6% or $188.8 million of the total in 2025. Going forward, the vaccine efficacy segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by applications, at a CAGR of 8.6% during 2025-2030.
The ABSL-3 lab services market is segmented by species into rodent, non-human primate (NHP) and other species. The rodent market was the largest segment of the ABSL-3 lab services market segmented by species, accounting for 52.6% or $279 million of the total in 2025. Going forward, the other species segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by species, at a CAGR of 8.7% during 2025-2030.
The ABSL-3 lab services market is segmented by service types into efficacy studies, pharmacokinetics/pharmacodynamics (PK/PD) studies, investigational new drug (IND)-enabling packages, supporting assays and other service types. The efficacy studies market was the largest segment of the ABSL-3 lab services market segmented by service types, accounting for 33.8% or $179 million of the total in 2025. Going forward, the investigational new drug (IND)-enabling packages segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by service types, at a CAGR of 8.8% during 2025-2030.
The ABSL-3 lab services market is segmented by end user into pharmaceutical and biotech companies, contract research organizations (CROs), academic and research institutions, not-for-profit research organizations, governmental institutes and public health agencies, defense/military and other end users. The pharmaceutical and biotech companies market was the largest segment of the ABSL-3 lab services market segmented by end user, accounting for 43.9% or $232.9 million of the total in 2025. Going forward, the academic and research institutions segment is expected to be the fastest-growing segment in the ABSL-3 lab services market segmented by end user, at a CAGR of 8.4% during 2025-2030.
The global ABSL-3 (animal biosafety level 3) lab services market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 20.87% of the total market in 2024. University of Pennsylvania (Jurado Lab) was the largest competitor with a 2.81% share of the market, followed by Boston University with 2.70%, University of South Florida (USF Health) with 2.45%, University of South Carolina, with 2.37%, University of Minnesota, with 2.34%, University of California (UC) with 2.13%, Southern Research with 1.81%, Tulane University with 1.62%, Texas Biomed (Texas Biomedical Research Institute) with 1.38% and SoBran, Inc. with 1.25%.
The top opportunities in the ABSL-3 lab services market segmented by disease area will arise in the respiratory infections segment, which will gain $104.8 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by pathogen types will arise in the bacteria segment, which will gain $127.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by applications will arise in the vaccine efficacy segment, which will gain $94.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the rodent segment, which will gain $132.5 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the efficacy studies segment, which will gain $87.6 million of global annual sales by 2030. The top opportunities in the ABSL-3 lab services market segmented by species will arise in the pharmaceutical & biotech companies segment, which will gain $107.8 million of global annual sales by 2030. The ABSL-3 lab services market size will gain the most in the USA at $78.3 million.
Player-adopted strategies in the ABSL-3 lab services market include focus on expanding their business capabilities through new expansions.
Market-trend-based strategies for the ABSL-3 lab services market include focus on expanding specialized high-containment animal research capabilities, scaling infrastructure through multi-site expansion and partnerships with public institutions to improve geographic coverage and access to certified containment facilities, expanding specialized high-containment animal research capabilities, particularly for non-human primate studies that support advanced vaccine and therapeutic development, and aligning facility design, operations, and quality systems.
To take advantage of the opportunities, the analyst recommends the ABSL-3 (animal biosafety level 3) lab services companies to focus on expanding high-containment animal research capabilities, focus on multi-site infrastructure expansion and public sector partnerships, focus on expanding high-containment animal research capabilities, focus on regulatory alignment and certification readiness, focus on viral infections segment expansion, focus on expanding viral research services, expand in emerging markets, continue to focus on developed markets, focus on expanding and optimizing distribution networks, focus on structured value-based pricing with risk and compliance alignment, build authority through targeted educational promotion, strengthen credibility with proof and precision targeting and focus on skilled talent development and research-aligned engagement.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 ABSL-3 Lab Services Market, Supply Chain Analysis
8 Information on the Opportunities and Threats, Challenges and Value Creation Levers for ABSL-3 Lab Services
9 Information on the Impact or Potential Impact of NAMs on ABSL-3 Lab Services Covering Information Such as Indications Where NAMs Are Advancing the Fastest and Adoption Trends in Infectious Disease
10 Information on Available Services and Operational Benchmarks for Well-Run ABSL3 Lab Facilities At Global Level, Based on Available Secondary Information
11 Information on Primary Differentiators Among the Top 5 ABSL-3 (Animal Biosafety Level 3) Lab Service Providers At Global Level, Based on Available Secondary Information
12 Information on the Type of Funding Available for ABSL-3 Lab Services (Govt, Private Equity, Venture Funding, Other Funding) and Overall Investment Dynamics
13 List of Companies/Institutions That Are Funding Infectious Disease Work and Companies That Are Active in Vaccines/Antivirals
14 Information on Current Regulations That Affect Research Requiring ABSL-3 (Animal Biosafety Level 3) Work in the USA, Europe and Asia-Pacific
15 Information on Regulatory Policy Changes That Are Anticipated to Have An Impact on Demand for ABSL-3 (Animal Biosafety Level 3) Work
16 Information on Biggest Anticipated Demands in the Coming 5-10 Years (Vaccines, Antimicrobial Resistance, Flu/COVID Preparedness, Biodefense)
18 Global ABSL-3 Lab Service Market Attractiveness Scoring and Analysis
19 Major Market Trends
20 ABSL-3 Lab Services Growth Analysis and Strategic Analysis Framework
21 Global ABSL-3 Lab Services Total Addressable Market (TAM) Analysis
22 Global ABSL-3 Lab Services Market Segmentation
23 ABSL-3 Lab Services Market, Regional and Country Analysis
24 Asia-Pacific Market
25 Europe Market
26 Rest of the World (ROW) Market
27 Competitive Landscape and Company Profiles
28 Other Major and Innovative Companies
30 ABSL-3 Lab Services Market - Company Scoring Matrix
31 Key Mergers and Acquisitions
32 Recent Developments in ABSL-3 Lab Services
33 Opportunities and Strategies
34 ABSL-3 (Animal Biosafety Level 3) Lab Services Market, Conclusions and Recommendations
35 Appendix
Executive Summary
ABSL-3 (Animal Biosafety Level 3) Lab Global Market Opportunities and Strategies to 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global ABSL-3 (animal biosafety level 3) lab market as it emerges from the COVID-19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 13 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for ABSL-3 (animal biosafety level 3) lab? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The ABSL-3 (animal biosafety level 3) lab market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider ABSL-3 (animal biosafety level 3) lab; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis and Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Regional and Country Analysis - Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by disease area, by pathogen types and by applications, by species, by service types and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Recent Developments Information on recent developments in the market covered in the report.
- Market Opportunities and Strategies Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations - This section includes recommendations for hostels providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
1) By Disease Area: Respiratory Infections; Viral Infections; Other Disease Areas
2) By Pathogen Types: Viruses; Bacteria; Fungi; Other Pathogen Types
3) By Applications: Antiviral Research and Development (R&D); Vaccine Efficacy; Transmission; Other Applications
4) By Species: Rodent; Non-Human Primate (NHP); Other Species
5) By Service Types: Efficacy Studies; Pharmacokinetics/Pharmacodynamics (PK/PD) Studies; Investigational New Drug (IND)-Enabling Packages; Supporting Assays; Other Service Types
6) By End User: Pharmaceutical and Biotech Companies; Contract Research Organizations (CROs); Academic and Research Institutions; Not-For-Profit Research Organizations; Governmental Institutes and Public Health Agencies; Defense/Military; Other End Users
Companies Mentioned: University of Pennsylvania (Jurado Lab); Boston University; Constellation Brands Inc; Carlsberg Breweries AS; Molson Coors Brewing Company
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Europe; North America; Rest of the World
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; ABSL-3 (animal biosafety level 3) lab indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- University of Pennsylvania (Jurado Lab)
- Boston University
- Constellation Brands Inc
- Carlsberg Breweries AS
- Molson Coors Brewing Company
- Kirin Holdings Co. Ltd.
- Diageo plc
- Bacardi Limited
- Sapporo Breweries Ltd.
- The Boston Beer Company Inc.
- Australian Centre for Disease Preparedness (ACDP)
- Elizabeth Macarthur Agricultural Institute (EMAI)
- WuXi AppTec
- JOINN Laboratories
- YEBIO Bioengineering
- Harbin Veterinary Research Institute (HVRI, CAAS)
- Institute of Microbiology, Chinese Academy of Sciences (IMCAS)
- Institute of Life Sciences (ILS), Bhubaneswar
- Indian Veterinary Research Institute (IVRI)
- Biovet Pvt. Ltd.
- Biosafe Lab India Pvt. Ltd.
- National Research and Innovation Agency (BRIN)
- National Institute of Animal Health (NIAH)
- Institute of Medical Science, University of Tokyo (IMSUT)
- Woojung Bio
- International Vaccine Institute (IVI, Seoul)
- Jeonbuk National University
- Korea Research Institute of Bioscience and Biotechnology (KRIBB)
- IMeBIO Laboratories
- Czech Centre for Phenogenomics
- Helmholtz Munich
- VetBioNet
- MUNI SCI
- Labover
- Charles River Laboratories
- Friedrich-Loeffler-Institut (FLI)
- University of Padua
- VISAVET
- INIA-CISA (Animal Health Research Centre)
- IRTA CReSA (Animal Health Research Center)
- ISGlobal
- Moredun Research Institute
- University of South Florida (USF Health)
- University of California (UC)
- University of Minnesota
- University of South Carolina
- Southern Research
- Texas Biomedical Research Institute (Texas Biomed)
- Tulane University
- Jurado Lab
- SoBran, Inc.
- BIOQUAL, Inc.
- Illinois Institute of Technology Research Institute (IITRI)
- Lovelace Biomedical
- TICRO Bioservices
